China Medical University Hospital Named to Newsweek's World's Best Specialized Hospitals 2027 for Neurosurgery
CMUH is the only hospital in Taiwan recognized in the Neurosurgery category, reflecting its strengths in complex neurosurgery, integrated neurological care and cell therapy
China Medical University Hospital’s Department of Neurosurgery has been named to Newsweek’s World’s Best Specialized Hospitals 2027 for the first time, placing among the world’s top 125 in Neurosurgery and standing as the only hospital in Taiwan listed in this specialty. The recognition reflects CMUH’s long-standing strengths in complex neurological care and innovative treatments.
CMUH is the only hospital in Taiwan recognized in the Neurosurgery category, reflecting its strengths in complex neurosurgery, integrated neurological care and cell therapy
TAICHUNG, Sept. 21, 2026 /PRNewswire/ -- China Medical University Hospital (CMUH) has been named to Newsweek's World's Best Specialized Hospitals 2027 for Neurosurgery, the only hospital in Taiwan to be included in the Neurosurgery ranking.
The recognition reflects CMUH's long-standing strengths in complex neurosurgery, integrated care for acute and high-risk neurological conditions, precision medicine and translational cell therapy.
Newsweek's World's Best Specialized Hospitals 2027, developed with Statista, ranks leading hospitals across 13 medical specialties, with 125 hospitals worldwide included in the Neurosurgery ranking. The evaluation is based on international peer recommendations, hospital and specialty accreditations, and the implementation of Patient-Reported Outcome Measures (PROMs).
Precision neurosurgery and integrated care for complex neurological disorders
Der-Yang Cho, M.D., Ph.D., superintendent of CMUH, said the recognition reflects years of clinical experience, research innovation and multidisciplinary collaboration.
"At CMUH, our approach begins with the needs of each patient," Cho said. "By integrating neurosurgery with our stroke, emergency and trauma, and critical care teams, we provide coordinated care for patients with acute and highly complex neurological disorders."
CMUH performs more than 5,000 neurosurgical procedures each year, including surgery for brain tumors, cerebrovascular disease, spinal disorders and other complex conditions. The hospital combines advanced neuroimaging and intraoperative functional monitoring to remove tumors while preserving speech, movement and other critical functions, and applies artificial intelligence in clinical workflows to speed diagnosis and treatment decisions for intracranial hemorrhage, stroke and severe traumatic brain injury.
CAR001 clinical trial offers new possibilities for recurrent malignant brain tumors
One of CMUH's key areas of translational innovation is CAR001, an allogeneic, off-the-shelf CAR gamma delta (γδ) T-cell therapy developed with Ever Supreme Bio Technology Co., Ltd. (Ever Supreme), a spin-off of the China Medical University Healthcare System. The therapy uses mRNA-engineered γδ T cells targeting HLA-G and is currently being evaluated in relapsed or refractory solid tumors, including glioblastoma.
Chun-Chung Chen, M.D., director of the Department of Neurosurgery at CMUH, noted that CAR001 remains investigational and that the outcome of a single participant cannot be generalized to all patients.
One participant with recurrent glioblastoma had experienced rapid disease progression after prior treatment and had been given an estimated life expectancy of three to six months. Following molecular and target assessment, she was enrolled in the CAR001 trial. After treatment, she showed progressive neurological and functional improvement and regained mobility. Follow-up imaging showed no evidence of the original tumor lesion, and her overall condition has remained stable.
"This response provides an important clinical signal and supports further investigation of cell therapy for patients with recurrent malignant brain tumors who have limited conventional treatment options," Chen said.
Looking ahead, CMUH is expanding research in exosomes, mitochondrial medicine and regenerative therapies, with potential applications in Alzheimer's disease, Parkinson's disease, stroke, spinal cord injury and other neurological disorders.
"We will continue to connect clinical medicine, advanced technology and translational research around patient needs," Cho said. "Our goal is not only to provide access to advanced treatment, but also to develop new therapies that originate in Taiwan."
View original content to download multimedia:https://www.prnewswire.com/news-releases/china-medical-university-hospital-named-to-newsweeks-worlds-best-specialized-hospitals-2027-for-neurosurgery-302884643.html
SOURCE China Medical University Hospital
